Performance and Clinical Evaluation of the 92-Gene Real-Time PCR Assay for Tumor Classification

Abstract

Accurate determination of cancer origin is necessary to guide optimal treatment but remains a diagnostic challenge. Gene expression profiling technologies have aided the classification of tumors and, therefore, could be applied in conjunction with clinicopathologic correlates to improve accuracy. We report an expanded version of the previously

A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors

“…The 92-gene assay routinely includes laser microdissection of tumor tissue, which is a key step that contributes to classification accuracy. 19,20 Feasibility analysis was performed to determine whether a subset of genes within the 92-gene biomarker panel could have value in predicting the site of origin for neuroendocrine tumors. Specifically, 15 genes were identified that showed reasonable discrimination between neuroendocrine tumors from different anatomic sites in this set of tested Shown are the four cases with discrepancy between reference diagnosis and assay prediction with detail on patient history, case work-up, and prediction results.…”

“…14 Traditionally, pathologists have used panels of protein-based immunohistochemical stains for tumor classification, but the potential advantage of molecular tests is readily apparent. In recent years, RNA expression-based classification of tumors has become an attractive standardized approach to aiding in the diagnosis and subclassification of tumors [19][20][21][22][23][24][25] and for individualized therapy applications. [26][27][28] In the coming years, gene expressionbased analysis may serve as a complementary approach to genome-wide DNA analysis of tumors for individualized therapy.…”

Gene expression profiling and its use in adenocarcinomas of unknown primary origin: A case report

“…Gene expression profiling assays correctly identified the site of origin in 85% of cases in blinded studies of tumors of known origin, and was found to favorably compare with IHC staining (17,18). The best use of gene expression profiling to form a diagnosis appears to be for cases with inconclusive IHC staining.…”

“…The patient underwent gene expression profiling with CancerTYPE ID (BioTheranostics, Inc., San Diego, CA, USA), in order to aid in the identification of the primary site. The CancerTYPE ID assay is a 92-gene reverse transcription-polymerase chain reaction assay that allows the identification of 30 main tumor types and 54 subtypes (17). There is also another gene expression profiling assay currently commercially available, which uses 64 tissue-specific microRNAs to enable the identification of 42 tumor types, using a microarray technology known as the Cancer Origin Test (Rosetta Genomics, Rehovot, Israel) (18).…”

The Diagnosis and Management of Neuroendocrine Carcinoma of Unknown Primary

“…Recently, Erlander et al recently reported on the use of a 92-gene real-time PCR assay for tumor classification used to compare the gene expression profile of an unknown sample to that of known tumors in a reference database (Erlander, Ma et al 2011). This reference database includes NETs, such as small intestinal, BP, and pancreatic NETs.…”